-
Your selected country is
Ireland
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
CD38 polyclonal antibody, also known as ADP-ribosyl cyclase, is a type II transmembrane glycoprotein able to transform NADP+ into cyclic ADP-ribose, NAADP+ and ADP-ribose. CD38 is expressed at variable levels on the majority of hematopoietic cells (during early differentiation and activation) and in some non-hematopoietic tissues. It is expressed at high levels on plasma cells (CD38+++) and, due to its strong reactivity, CD38 is considered a "specific plasma cell marker"; but it is also present on thymocytes, activated T cells, NKs monocytes, and basophils. CD38 has been reported to play a role as regulator (positive and negative) of cell activation and proliferation, and to be involved in adhesion between lymphocytes and endothelial cells. The multi-epitope anti-human CD38 is a monoclonal antibody designed to be used as a direct immunofluorescence reagent in order to identify cells that express the CD38 antigen by flow cytometry.
The simultaneous assessment of the expression of CD38 and CD138 represents the best combination of markers for the identification of plasma cells.
No Citations are available for this Product
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For In Vitro Diagnostic Use.
23-22942-00
Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.